Renal Anemia

Front Cover
Onyekachi Ifudu
Springer Science & Business Media, Jul 31, 2002 - Medical - 145 pages
0 Reviews
Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.
  

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

III
1
IV
9
V
15
VI
29
VII
37
VIII
49
IX
65
X
81
XII
99
XIII
107
XIV
115
XV
123
XVI
129
XVII
139
XVIII
141
Copyright

XI
89

Common terms and phrases

Bibliographic information